ImmunoGenesis

Houston, TX · Founded 2019 · Privately Held (backing)

Developer of immuno-oncology therapeutics designed to create cold tumor treatments. ImmunoGenesis is based in Houston, TX and was founded in 2019. It was valued at $142 million at its later-stage round in May 2025, the last priced event on record. It has raised $67.2 million across 1 recorded round; the latest was a $44.4 million early-stage round in Mar 2024.

PMV mark · valuation
$142.0M
Oct 2026
Priced at
its later-stage round
May 2025
Total raised
$67.2M
Last round
Early Stage VC
Mar 2024
How much has ImmunoGenesis raised?
$67.2Macross 1 recorded rounds · Mar 2024 – Mar 2024

Most recently, ImmunoGenesis raised $44.4M in its Early Stage VC (Mar 2024).

Free account
More of ImmunoGenesis with a free account
  • ·The complete investor list: 13 names
  • ·Watch ImmunoGenesis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

ImmunoGenesis round by round

1 rounds
Mar 2024Early Stage VC$44.4MSEC filing▮
88 investors participated

How much has ImmunoGenesis raised?

ImmunoGenesis has raised $67.2 million in total; 1 of its rounds is on record. The largest on record was a $44.4 million early-stage round in Mar 2024.

ImmunoGenesis has filed 1 Form D with the SEC, most recently in Apr 2024 ($44.4 million sold to 88 investors).

ImmunoGenesis investors

13 investors are on record for ImmunoGenesis, including Service Provider Capital, ADIT Ventures, Magnetar Capital and PEAK6 Strategic Capital. By type, the record holds 4 venture capital firms, 2 family offices and 1 hedge fund. The early-stage round in Mar 2024 drew 88 investors.

For fundraisers
Raising for a company like ImmunoGenesis?

13 investors have backed ImmunoGenesis.

See all 13 investors →

Frequently asked about ImmunoGenesis

How much has ImmunoGenesis raised?
ImmunoGenesis has raised $67.2M in total across 1 recorded funding rounds.
When was ImmunoGenesis's last funding round?
ImmunoGenesis's most recent recorded round was Early Stage VC in Mar 2024, raising $44.4M.